Literature DB >> 9299577

Tumour suppressor genes in prostate cancer.

D MacGrogan1, R Bookstein.   

Abstract

Inactivation of tumour suppressor gene function is a critical step in the development of human neoplasia. The Rb and CDKN2 tumour suppressor genes are inactivated in many tumour types, including the late stages of prostate cancer, and appear to function in the same suppressor pathway. p53, another major tumour suppressor is also mutated in a subset of advanced-stage prostate carcinomas. E-cadherin and other cell adhesion genes, which have been characterized as suppressors of the metastatic phenotype, are inactivated or downregulated during progression to advanced prostate cancer and have been associated with poor clinical outcome. The early genetic events involved a prostatic neoplasia are poorly understood, but loss of as yet undiscovered tumour suppressor genes may play a role in the initiation of this disease.

Entities:  

Mesh:

Year:  1997        PMID: 9299577     DOI: 10.1006/scbi.1997.0048

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  15 in total

1.  High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22.

Authors:  Z H Arbieva; K Banerjee; S Y Kim; S L Edassery; V S Maniatis; S K Horrigan; C A Westbrook
Journal:  Genome Res       Date:  2000-02       Impact factor: 9.043

2.  Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.

Authors:  Khanh H Nguyen; Paul Hachem; Li-Yan Khor; Naji Salem; Kelly K Hunt; Peter R Calkins; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

3.  [Therapy of castration-resistant prostate cancer].

Authors:  Michael Rauchenwald; Thomas Bauernhofer; Maria De Santis; Thorsten Füreder; Wolfgang Höltl; Gero Kramer; Steffen Krause; Wolfgang Loidl; Renée Oismüller; Andreas Reissigl; Nikolaus Schmeller; Walter Stackl; Franz Stoiber; Michael Krainer
Journal:  Wien Klin Wochenschr       Date:  2012-07-20       Impact factor: 1.704

4.  Deregulation of Internal Ribosome Entry Site-Mediated p53 Translation in Cancer Cells with Defective p53 Response to DNA Damage.

Authors:  Marie-Jo Halaby; Benjamin R E Harris; W Keith Miskimins; Margot P Cleary; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2015-09-21       Impact factor: 4.272

5.  Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation.

Authors:  Y Liu; E Kyle; R Lieberman; J Crowell; G Kellof; R C Bergan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

Review 6.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

7.  Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase.

Authors:  Hui-Kuan Lin; Liang Wang; Yueh-Chiang Hu; Saleh Altuwaijri; Chawnshang Chang
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

8.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

9.  A transgenic mouse model for early prostate metastasis to lymph nodes.

Authors:  Hyun-Kyung Ko; Shin Akakura; Jennifer Peresie; David W Goodrich; Barbara A Foster; Irwin H Gelman
Journal:  Cancer Res       Date:  2014-02-01       Impact factor: 12.701

10.  Induction of the p53 Tumor Suppressor in Cancer Cells through Inhibition of Cap-Dependent Translation.

Authors:  Benjamin R E Harris; Defeng Wang; Ye Zhang; Marina Ferrari; Aniekan Okon; Margot P Cleary; Carston R Wagner; Da-Qing Yang
Journal:  Mol Cell Biol       Date:  2018-04-30       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.